Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress, J Control Release, vol.161, pp.175-87, 2012. ,
Combination antitumor therapy with targeted dual-nanomedicines, Adv Drug Deliv Rev, vol.115, pp.23-45, 2017. ,
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity, Adv Drug Deliv Rev, vol.91, pp.3-6, 2015. ,
The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo, Adv Drug Deliv Rev, vol.65, pp.71-80, 2013. ,
To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?, J Control Release, vol.244, pp.108-129, 2016. ,
Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using copper-64 liposomes, ACS Nano, vol.9, pp.6985-95, 2015. ,
Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy, Pharmacol Res, vol.126, pp.109-131, 2017. ,
Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment, Adv Drug Deliv Rev, vol.119, pp.120-162, 2017. ,
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology, Adv Drug Deliv Rev, vol.66, pp.2-25, 2014. ,
Use of single chain antibody derivatives for targeted drug delivery, Mol Med, vol.22, pp.258-70, 2016. ,
Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy, Theranostics, vol.2, pp.3-44, 2012. ,
Ligand-targeted theranostic nanomedicines against cancer, J Control Release, vol.240, pp.267-86, 2016. ,
Antibody fragments as nanoparticle targeting ligands: a step in the right direction, Chem Sci, vol.8, pp.63-77, 2017. ,
Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging, Biomaterials, vol.29, pp.4012-4033, 2008. ,
Surface engineering of iron oxide nanoparticles for targeted cancer therapy, Acc Chem Res, vol.44, pp.853-62, 2011. ,
Covalent conjugation of cysteine-engineered scFv to PEGylated magnetic nanoprobes for immunotargeting of breast cancer cells, RSC Adv, vol.6, pp.37099-109, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01309513
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, vol.235, pp.177-82, 1987. ,
HER2-positive breast cancer, Lancet, vol.389, pp.2415-2444, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02464524
The development of stable aqueous suspensions of PEGylated SPIONs for biomedical applications, Nanotechnology, vol.19, p.465608, 2008. ,
Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells, Biomaterials, vol.31, pp.1307-1322, 2010. ,
Synthesis and in vitro evaluation of fluorescent and magnetic nanoparticles functionalized with a cell penetrating peptide for cancer theranosis, J Colloid Interface Sci, vol.499, pp.209-226, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01515714
A method to confer Protein L binding ability to any antibody fragment, MAbs, vol.8, pp.379-88, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02297085
Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging, Nanomedicine, vol.11, pp.2051-60, 2015. ,
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes, Cancer Cell, vol.10, pp.515-542, 2006. ,
The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines, Breast Cancer (Auckl), vol.4, pp.35-41, 2010. ,
ScFvdecorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2(+) breast cancer, Adv Healthc Mater, vol.3, pp.1792-803, 2014. ,
Endocytosis of nanomedicines, J Control Release, vol.145, pp.182-95, 2010. ,
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats, Nanomedicine (Lond), vol.3, pp.703-720, 2008. ,
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles, Chem Soc Rev, vol.44, pp.8576-607, 2015. ,
Biodistribution of ultrasmall iron oxide particles in the rat liver, J Magn Reson Imaging, vol.13, pp.594-603, 2001. ,
In vivo HER2-targeted magnetic resonance tumor imaging using iron oxide nanoparticles conjugated with anti-HER2 fragment antibody, Mol Imaging Biol, vol.18, pp.870-876, 2016. ,